SAN DIEGO, Aug. 28, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members
of its senior management team will participate in the upcoming
investor conferences:
- Wells Fargo Global Healthcare Conference – Presenting on
Wednesday, September 4, at
8:30 AM EDT in Boston
- Citi Biotech Conference – Hosting investor meetings on
Thursday, September 5, in
Boston
A live audio webcast of the Wells Fargo presentation will be
available under the investor relations section of Arena's website
at www.arenapharm.com. A replay of the presentation will be
available for 30 days following the events.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology and pharmacokinetics to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility.
Etrasimod (APD334), with potential utility in a broad range of
immune and inflammatory conditions, is being evaluated in
later-stage clinical programs in ulcerative colitis (UC) and
Crohn's disease (CD), as well as in programs for other indications
such as atopic dermatitis. Arena is also evaluating olorinab
(APD371) in a Phase 2 program for gastrointestinal pain. Arena
continues to assess other earlier research and development stage
drug candidates, including APD418 for decompensated heart
failure.
Arena has additional license agreements and partnerships,
including with United Therapeutics (ralinepag in a Phase 3 program
for pulmonary arterial hypertension), Everest Medicines Limited
(etrasimod in Greater China and
select Asian countries), Boehringer Ingelheim International GmbH
(undisclosed target – preclinical), Outpost Medicine, LLC
(undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai
Inc. (BELVIQ® – marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about Arena's participation in and webcast of upcoming
investor conferences, Arena's drive, and the potential of Arena's
assets, programs, licenses, and partnerships. For such statements,
Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially
from Arena's expectations. Factors that could cause actual results
to differ materially from the forward-looking statements include
those disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-participate-in-upcoming-investor-conferences-300908135.html
SOURCE Arena Pharmaceuticals, Inc.